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ABSTRACT
Lung cancer is the leading cause of cancer death in
Canada. The organization of health care services is
central to the delivery of accessible, high-quality
medical care and may be one factor that influences
patient outcome. An exciting opportunity arose for
clinicians to initiate the redesign of lung cancer ser-
vices provided by three institutions in the Greater
Toronto Area. This qualitative report describes the
integrated lung cancer network that they developed,
the innovation it has facilitated, and the systematic
approach being taken to evaluate its impact. Avail-
able clinical resources were deployed to restructure
services along patient-centred lines and to provide
greater access to the specialist lung cancer team. A
non-hierarchical clinical network was established that
consolidates the lung cancer team. A multi-institu-
tional and multidisciplinary tumour board and com-
prehensive thoracic oncology clinics are at its core.
This innovative organizational paradigm considers all
of the available services at each facility and aims to
fully integrate specialists across the three institutions,
thereby maximizing resource utilization. We believe
that this paradigm may have wider applicability. The
network is currently working to complete a current
program of further service improvements and to ob-
jectively assess its impact on patient outcome.
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1. INTRODUCTION
1.1 Demographics and Treatment
Lung cancer is the leading cause of cancer death in
Canada, and overall survival has changed little in
recent decades. In 2007, an estimated 23,300 new
patients will be diagnosed, and 19,900 lung cancer
patients will die. For patients diagnosed in 1996–
1998, the age-standardized 5-year relative survival
ratio in Ontario was 16%. About 80% of patients
develop non-small-cell lung cancer (NSCLC). Patients
with operable early-stage NSCLC have the best prog-
nosis, but most patients present with locally advanced
or metastatic NSCLC, whose 5-year survival rates are
approximately 10% and 5% respectively. Interest is
growing among specialists, patients, and providers
concerning the organization and design of lung can-
cer services, and the effect that improvements might
have on patient outcomes, including survival 1.
1.2 Lung Cancer Services
Despite conflicting evidence, data are available to
suggest links between tumour size, treatment intent,
and prognosis 2. Prolonged patient journeys may
therefore carry a risk of lung cancer progression that
could affect treatment options 3. Acknowledging that
appreciable waits have been documented for Cana-
dian lung cancer patients requiring surgery or radio-
therapy, the Ontario Cancer Plan 2005–2008 4
includes development of increased capacity and of
rapid-access strategies. Substantial investment in
capital projects has occurred, including construction
of several community cancer centres with radio-
therapy facilities that will bring treatment closer to
home for many patients. Improvements have already
been seen in wait times for radiation treatment and
cancer surgery.
The present report describes an innovative reor-
ganization undertaken by colleagues at the Odette
Cancer Centre (OCC—formerly the Toronto–
Sunnybrook Regional Cancer Centre) and two uni-
versity-affiliated community teaching hospitals
located in Ontario, the Toronto East General Hospi-
tal (TEGH—approximately 9 km southeast of OCC) and
The Scarborough Hospital (TSH—approximately
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14 km east of OCC), to improve delivery and accessi-
bility of specialist lung cancer services.
2. REDESIGNING LOCAL LUNG CANCER
SERVICES
2.1 The Impetus
The OCC is part of Sunnybrook Health Sciences
Centre (SHSC). The sixth-largest comprehensive
cancer centre in North America, OCC is one of two
regional cancer centres in Toronto. It provides ex-
pertise in medical and radiation oncology and ac-
cess to diagnostic and medical specialists. Lung
cancer surgery for patients in the OCC catchment
area is performed at several hospitals. In addition,
cross-appointed thoracic surgeons from TEGH can
also see and operate on patients at SHSC. Most pa-
tients fall within the catchment areas of the TEGH
and TSH, both of which have thoracic surgeons,
medical oncologists, and respirology and diagnos-
tic services on site and both of which refer their
patients to OCC for radiotherapy.
Recently, clinical colleagues from the foregoing
institutions agreed that the lung cancer services they
provide would benefit from consolidation and that
the process would afford an opportunity to strengthen
patient-centred care. The interdependence and reli-
ance of these three institutions indicated excellent
suitability for a collaboration. The integrated service
aimed to
• be patient-centred, to have an academic focus,
and to make use of available resources to facili-
tate decision-making and to provide access to
evidence-based multidisciplinary lung cancer
care.
• provide a coordinated patient journey from ini-
tial suspicion to diagnosis and treatment of lung
cancer.
• increase the number of patients seen when their
disease is in its early stages and when they are
candidates for curative-intent treatment, and to
increase the opportunities to offer patients clini-
cal trials and studies.
2.2 The Model
Proponents of the consolidation felt that a multi-in-
stitutional, multidisciplinary lung cancer tumour
board (LCTB), multidisciplinary lung cancer clinics,
and strengthened links between the specialist team
and primary care were all central to achieving the
stated aims. Delineating a clear organizational struc-
ture, placing the multidisciplinary LCTB at the centre
of the service, and formally linking the thoracic sur-
gery centres with the regional cancer centre (Figure 1)
all meet specific recommendations made in both the
Thoracic Surgical Oncology and Multidisciplinary
Cancer Conference Standards which are produced by
Cancer Care Ontario’s Program in Evidence-Based
Care 5.
The weekly LCTB started at OCC in May 2005 and
is held at a time that allows for regular attendance by
specialists from OCC, TEGH, and TSH. It is accredited
for continuing medical education through the Royal
College of Physicians and Surgeons of Canada. Most
of the cases discussed involve patients who might be
candidates for radical multimodality treatment or
whose disease poses clinical challenges. When ap-
propriate, patients are considered for clinical trials.
For example, in the 11 months before and after the
LCTB started meeting, 14 and 32 patients respectively
were enrolled in the group’s highest-recruiting NSCLC
study. An average of about 10 cases are discussed
each week, and all institutions are well represented
(about 55% of cases from OCC, 25% from TEGH, and
20% from TSH).
The second strand of the remodelled service is
weekly combined lung cancer clinics. In these clin-
ics, patients can be simultaneously evaluated by mul-
tiple specialities, providing optimal management. To
improve patient access, the clinics take place at TEGH
and  OCC. All OCC staff can now refer patients with
malignant thoracic disease (including metastases) to
the TEGH/SHSC surgeons who staff the clinic. A num-
ber of thoracic surgeons also take part in the high
dose rate brachytherapy service at OCC.
3. FURTHER IMPROVEMENTS
Several additional improvement projects are currently
underway:
• A time-to-treatment initiative with a consolidated
referral pathway is being implemented between
family medicine, respirology (OCC), and thoracic
surgery (TEGH) for patients with suspected lung
cancer. A patient-flow coordinator provides the
next available consultation with an appropriate
specialist closest to the patient and can book in-
vestigations using dedicated imaging slots. The
impetus for this consolidation was the success of
earlier redesign work carried out at TEGH that had
reduced to 30 from 128 days the overall time from
suspicious chest radiograph to diagnosis 6. A
Web-based database will record patient care
timelines, clinical management details, and out-
comes from this initiative. The rollout will in-
clude interactive education meetings with primary
care physicians.
• A weekly rapid-access multidisciplinary clinic
specifically for patients with resected and locally
advanced lung cancer has recently been estab-
lished to fast-track decision-making and to coor-
dinate multimodal treatment in patients who may
be being managed with curative intent. This clinic
model is new. Wait times are 7 days or fewer, withDAHELE et al.
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urgent cases often being seen within 48 hours.
Patient and staff satisfaction will be assessed, and
information resources specific to these patient
groups are currently being developed.
•A   LCTB database has been developed that will pro-
vide searchable information, including a record
of participants, patient demographics, team de-
cisions, and changes to provisional management
plans, diagnosis, and staging. Thus, objective data
is being gathered that will permit assessment of
the effect of the LCTB.
• A study is underway to compare cohorts of pa-
tients referred to lung cancer team members be-
fore and after initiation of the service changes.
Journey times and outcomes are among the vari-
ables that are being studied. This ongoing work
will generate quantitative data that will help to
benchmark the service, to assess the effect of ser-
vice changes on patient outcome, and to provide
an impetus for continued improvement. That
study will be the subject of a future publication.
4. CONCLUSION
Lung cancer management is challenging. Current
medical systems have long been criticized for being
fragmented and must evolve to deliver contemporary
lung cancer treatment to as many patients as possible.
The process of integrating clinical services across
three independent and geographically separate facili-
ties into a clearly defined service model has so far
succeeded in part because it has been clinician-led
with institutional support and buy-in, because it is
inclusive, and because it has resulted in improvements
for patients and physicians. A number of features
distinguish this network:
• a non-hierarchical structure that breaches barri-
ers and encourages cooperation,
• a two-way flow of personnel, and
• a multi-institutional LCTB.
We believe that this paradigm may find wider
application in the organization of cancer services.
The service model seeks to establish links with
primary care, to manage patient referrals to the hos-
pital-based lung cancer team, to provide local access
to multidisciplinary lung cancer clinics, to offer a
multidisciplinary rapid-access clinic for potentially
curable patients, to aid knowledge transfer, to facili-
tate working to generally agreed guidelines, and to
benefit clinical trial recruitment. It is also focused on
gathering relevant outcome data to support service
improvement. To date, the reorganization has required
considerable time and effort, and many ongoing chal-
lenges remain, including the delivery of local
multidisciplinary services to an ethnically and eco-
nomically diverse population. The success of the in-
tegrated lung cancer service rests firmly on the hard
work and commitment of all its staff.
Health care systems require continuous effort if
delivery of care is to be enhanced and sustained in an
increasingly challenging environment. However,
gains can potentially be made by incorporating ideas
FIGURE 1 Multi-institutional lung cancer service model. Links with primary care are being established to fast-track the referral of patients
with suspected lung cancer. The model also facilitates ad hoc surgical cooperation between Toronto East General Hospital (TEGH) and The
Scarborough Hospital (TSH). OCC = Odette Cancer Centre (formerly the Toronto–Sunnybrook Regional Cancer Centre); TB = tumour board;
HDR = high dose rate.CANCER SERVICE IMPROVEMENT
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from other sectors 7 and mechanisms to rapidly share
and adopt ideas and successes 8. Specific examples
of improvement methodologies, success stories, and
access to improvement communities can be found
on both the U.K. National Health Service Institute
for Innovation and Improvement and the North
American Institute for Healthcare Improvement Web
sites.
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